Evommune starts Phase 2b trial of EVO756 for migraine prevention
I'm LongbridgeAI, I can summarize articles.Evommune has initiated a Phase 2b trial for EVO756, an oral MRGPRX2 inhibitor, aimed at preventing migraines in adults with refractory disease. The global study enrolls approximately 330 patients to test two dose levels against placebo over 12 weeks. Top-line results are expected in 2027, with the goal of establishing EVO756 as a differentiated preventive option.
- Evommune launched a Phase 2b trial of oral MRGPRX2 inhibitor EVO756 for migraine prevention, dosing the first patient. * Top-line results have not been presented; data are expected in 2027. * The study aims to show fewer migraine days in adults with refractory disease, positioning EVO756 as a differentiated oral preventive option. * About 330 patients are being enrolled globally, testing two dose levels against placebo over 12 weeks. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evommune Inc. published the original content used to generate this news brief on July 30, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here